Abstract
Background: Osteoarthritis (OA) is a degenerative disorder affecting all joints & due to aphelia. The clinical manifestations of OA are swelling, pain & dysfunction of joints. Current non-pharmacological therapy mainly focuses on symptomatic treatment and may carry cardiovascular and gastrointestinal adverse effects. Nutraceuticals are preferred now a days owing to their safety and efficacy. TriNyros capsule consist of mixture of Rosa canina L. (Rosehip), Boswellia serrata and Harpagophytum procumbens (Devil`s claw) extract. These nutraceuticals are found to be effective as an anti-inflammatory, antioxidant, chondroprotective agent. Aim: Current post marketing phase IV surveillance study was conducted to investigate the effectiveness of TriNyros capsule in OA patient with and without comorbidity. Methods: Total 151 patients were enrolled in the study. All patients received cap. TriNyros containing [Rosehip 275 mg, IridoForceTM (Devil`s claw extract) 100 mg and Aflapin® 50 mg] twice daily for 90 days. Clinical assessment of symptoms included palpation tiredness, limitation of mobility, joint crepitus, swelling and redness. Osteoarthritis symptoms were measured using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Total European Quality of Life–5 Dimensions and visual analogue scale (VAS). Results: After 90 day’s treatment with Cap. TriNyros, WOMAC score reduced significantly from 39.62 + 11.95 to 13.36 + 4.82 (p
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
